Modified Huanglian Wendan Decoction (HLWDD) is used clinically for polycystic ovary syndrome with insulin resistance (PCOS‑IR), but its biological basis has been incompletely defined. The investigators applied an integrative approach combining network pharmacology, molecular docking and dynamics, batch‑specific chemical characterization, and in vivo evaluation to explore candidate active compounds, putative targets, and possible signaling associations relevant to HLWDD treatment of PCOS‑IR.
The formulation underwent HPLC fingerprinting to assess batch reproducibility; the authors report high reproducibility across batches. Untargeted chemical profiling using UHPLC‑HRMS/MS produced 997 candidate library assignments from the decoction. Among those, 118 features were designated as higher‑confidence detections. These chemical data were used to construct a candidate compound list for downstream network and docking analyses.
Using the compiled compound list, the study performed network pharmacology to identify compound–target relationships relevant to PCOS. Network analysis prioritized 136 candidate compounds and identified 532 overlapping PCOS‑related targets. Pathway enrichment from this network analysis highlighted the AGE‑RAGE signaling pathway as a prioritized biological process potentially linked to HLWDD activity in PCOS‑IR.
Representative compound–target complexes derived from the network analysis were subjected to molecular docking and then validated by 100‑ns molecular dynamics (MD) simulations. The docked complexes remained stable during the MD trajectories. Binding free energies calculated by MM/PBSA for these representative complexes were negative, indicating thermodynamically favorable interactions in the computational models. These computational results were presented as supportive evidence that selected HLWDD constituents could interact with targets implicated in the network analysis, including nodes in AGE‑RAGE–related signaling.
The in vivo component used a letrozole plus high‑fat diet Sprague‑Dawley rat model to recapitulate features of PCOS with insulin resistance. The study evaluated HLWDD effects on estrous cyclicity, ovarian morphology, metabolic parameters, reproductive hormones, inflammatory markers, and ovarian expression of molecular markers linked to AGE‑RAGE signaling. The abstract reports comparisons between a Model group and HLWDD‑treated groups including at least one high‑dose regimen; specific dose amounts and detailed dosing schedules were not reported in the abstract.
In treated animals, HLWDD produced multiple favorable phenotypic changes. The decoction promoted estrous‑cycle recovery and improved ovarian histology compared with the model group. Metabolically, HLWDD reduced fasting insulin and HOMA‑IR. Reproductive hormone levels and inflammatory markers were also decreased in HLWDD‑treated rats relative to the untreated model. The abstract presents these findings as evidence of phenotypic and biochemical improvement following HLWDD treatment in the PCOS‑IR rat model.
At the tissue and signaling level, HLWDD modulated ovarian expression of AGE and RAGE, as well as signaling proteins STAT3 and AKT1. In the high‑dose group, HLWDD reduced the phosphorylated STAT3 to total STAT3 ratio (p‑STAT3/STAT3) and increased the phosphorylated AKT to total AKT1 ratio (p‑AKT/AKT1) compared with the Model group. These changes are consistent with modulation of AGE‑RAGE/STAT3/AKT‑associated signaling in ovarian tissue following HLWDD treatment.
The integrated chemical, computational, and in vivo data together support an association between HLWDD treatment and modulation of AGE‑RAGE and downstream STAT3/AKT‑related signaling in a rat PCOS‑IR model. The authors explicitly note that while these findings indicate association and biologic plausibility, they do not establish causal pathway mediation. Key experimental details such as exact HLWDD dosing regimens, full quantitative results for biochemical endpoints, and the specific identities of all prioritized compounds and targets are not fully reported in the abstract. The work provides a multi‑modal foundation—chemical fingerprinting, network prediction, docking/MD validation, and phenotypic in vivo effects—that can guide hypothesis generation and more focused mechanistic studies to test whether HLWDD effects are mediated directly through AGE‑RAGE and related pathways.